Updated Results on Modakafusp Alfa (TAK-573) Safety and Efficacy; Phase 1/2 Study of RRMM Patients

REAL-TIMI 63B – TIMI STUDY GROUP

Immunocytokine Therapy International Myeloma Foundation

PDF) Immunotherapy of Multiple Myeloma: Current Status as Prologue

Updated Results on Modakafusp Alfa (TAK-573) Safety and Efficacy

Talquetamab in Pts with Relapsed/Refractory Multiple Myeloma

Current Status of Novel Agents for the Treatment of B Cell

Shebli ATRASH, Medical Doctor, Hematology Oncology

Discussing Modakafusp Alfa as a Potential Treatment in RRMM

Omar Nadeem's research works Dana-Farber Cancer Institute